COMPANY HISTORY
Milestone
SURGINEX's history toward RNA gene therapy development since its establishment in 2020
2026
05. Seung-min Yang, former Head of R&D at Dong-A ST, joins SURGINEX as Vice President and COO
04. Selected for the 2026 First-Round Health and Medical Technology R&D Program
04. Signed a strategic MOU with Rznomics to develop next-generation RNA gene therapies powered by precision-targeted LNP delivery
04. Selected as a portfolio company for the 2026 Super Gap Startup Project (DIPS), led by the Ministry of SMEs and Startups
2026
05. Seung-min Yang, former Head of R&D at Dong-A ST, joins SURGINEX as Vice President and COO
04. Selected for the 2026 First-Round Health and Medical Technology R&D Program
04. Signed a strategic MOU with Rznomics to develop next-generation RNA gene therapies powered by precision-targeted LNP delivery
04. Selected as a portfolio company for the 2026 Super Gap Startup Project (DIPS), led by the Ministry of SMEs and Startups
2024
07. 기술혁신형 중소기업(Inno-Biz) 선정
03. ㈜서지넥스 시리즈 B 투자유치
2023
06. Professor Hyuk-Jin Lee of Seoul National University (formerly Ewha Womans University) appointed Vice President and CSO
2024
07. Certified as a Technology Innovation SME (Inno-Biz)
03. Closed Series B financing
09. 2nd anniversary community service at Sarang-ui-jip (Caritas Convent, Bangbae-dong)
07. LMO research facility approval granted for the SURGINEX corporate research institute
05. Headquarters relocated and expanded to Omnibus Park Research Building, 222 Banpo-daero, Seocho-gu, Seoul
04. CEO Say-June Kim received the Minister of Science and ICT Commendation at the 55th Science Day
03. Registered as a full member of the Korea Bio Association
2022
2025
11. Received the Excellence Award at the 3rd Scale-up TIPS IR Summit
08. Selected for Scale-up TIPS (General Track, 2025 Round 3)
08. Selected as a national R&D project under the 2nd Korean ARPA-H Project (2025)
04. Selected for the 2025 Bio Research Data Validation Support Program, administered by the Korea Institute for Advancement of Technology Commercialization
2024
07. Certified as a Technology Innovation SME (Inno-Biz)
03. Closed Series B financing
2023
06. Professor Hyuk-Jin Lee of Seoul National University (formerly Ewha Womans University) appointed Vice President and CSO
2022
09. 2nd anniversary community service at Sarang-ui-jip (Caritas Convent, Bangbae-dong)
07. LMO research facility approval granted for the SURGINEX corporate research institute
05. Headquarters relocated and expanded to Omnibus Park Research Building, 222 Banpo-daero, Seocho-gu, Seoul
04. CEO Say-June Kim received the Minister of Science and ICT Commendation at the 55th Science Day
03. Registered as a full member of the Korea Bio Association
2021
12. Selected for the Innovative Company National Champion 1000 program
11. Selected for the Ministry of Employment and Labor's Future Youth Talent Development Program
10. Closed Series A financing
10. Built Odysseus, an AI-powered drug discovery platform
03. Certified as a Venture Company
2024
2024
2024
09. 2nd anniversary community service at Sarang-ui-jip (Caritas Convent, Bangbae-dong)
07. LMO research facility approval granted for the SURGINEX corporate research institute
05. Headquarters relocated and expanded to Omnibus Park Research Building, 222 Banpo-daero, Seocho-gu, Seoul
04. CEO Say-June Kim received the Minister of Science and ICT Commendation at the 55th Science Day
03. Registered as a full member of the Korea Bio Association
07. Certified as a Technology Innovation SME (Inno-Biz)
03. Closed Series B financing
07. 기술혁신형 중소기업(Inno-Biz) 선정
03. ㈜서지넥스 시리즈 B 투자유치
07. 기술혁신형 중소기업(Inno-Biz) 선정
03. ㈜서지넥스 시리즈 B 투자유치
2020
12. Filed SURGINEX trademark application
10. Secured Korea Technology Finance Corporation TECH Valley program guarantee
09. SURGINEX commenced operations (headquarters: 222 Banpo-daero, Seocho-gu, Seoul)
09. SURGINEX incorporated
2022
